SCHEMBL21045205

SCHEMBL21045205

Cc1cc(C(=O)NCCCc2ccc(-c3cnc4[nH]ccc4c3)cc2)n(C)n1

nearest known ligand 0.51

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 15/20 0.51
CD274 Q9NZQ7 1/20 0.49
RIPK1 Q13546 2/20 0.44
CDK8 P49336 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21045189 0.88 PIK3C3 (0.40) FLT3
SCHEMBL21045404 0.87 DRD5 (0.47)
SCHEMBL29411424 0.87 DRD5 (0.47)
SCHEMBL21045084 0.82 CD274 (0.53) FLT3CD274RIPK1CDK8
SCHEMBL21045313 0.81 FLT3 (0.47) FLT3CD274RIPK1CDK8
SCHEMBL21045216 0.80 ROCK2 (0.47)
SCHEMBL29411391 0.80 ROCK2 (0.47)
SCHEMBL21045409 0.80 CACNA1H (0.43) CDK8
SCHEMBL21045252 0.79 FLT3 (0.52) FLT3CD274RIPK1CDK8
SCHEMBL21045468 0.79 FLT3 (0.52) FLT3CD274RIPK1CDK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188035-A1 TUBULIN INHIBITORS LIN BIOSCIENCE LLC (US) 2025-06-12 US disclosed
US-12247010-B2 Tubulin inhibitors LIN BIOSCIENCE INC. (TW) 2025-03-11 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-20220089539-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2022-03-24 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
US-11040945-B2 Tubulin inhibitors LIN BIOSCIENCE PTY LTD. 2021-06-22 US disclosed
WO-2019113242-A1 TUBULIN INHIBITORS Lin BioScience, LLC (US) 2019-06-13 WO disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed
US-20190169127-A1 TUBULIN INHIBITORS LIN BIOSCIENCE INC. (TW) 2019-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089539-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB FLT3 1618/4885CD274 3858/4885RIPK1 3852/4885
US-12247010-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB FLT3 1618/4885CD274 3858/4885RIPK1 3852/4885
US-11040945-B2 Tubulin inhibitors TUBB3, TUBB1, TUBB FLT3 1618/4885CD274 3858/4885RIPK1 3852/4885
US-20250188035-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB FLT3 1618/4885CD274 3858/4885RIPK1 3852/4885
US-20190169127-A1 TUBULIN INHIBITORS TUBB3, TUBB1, TUBB FLT3 1618/4885CD274 3858/4885RIPK1 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.